Clinicopathologic analysis of acute myeloid leukemia in a single institution: Biphenotypic acute myeloid leukemia may not be an aggressive subtype

Journal of the Chinese Medical Association

Volumn 70, Issue 7, 2007, Pages 269-273

  Lee, Ming Yuan ^a,b   Tan, Tran Der ^a   Feng, An Chen ^a  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acute myeloid leukemia; Biphenotypic; Multilineage dysplasia; Therapy related; WHO classification

Indexed keywords

CYTARABINE; GYRASE INHIBITOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHROMOSOME ABERRATION; CLINICAL FEATURE; DISEASE ACTIVITY; DYSPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT INFORMATION; PHENOTYPE; PRACTICE GUIDELINE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; WORLD HEALTH ORGANIZATION;

EID: 34547903902     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(07)70003-5     Document Type: Article

References (17)

1. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Lugwig WD, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998;92:596-9.
2. Bene MC, Castordi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-6.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative group. Ann Intern Med 1985;103:620-5.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Tumours of Hematopoietic and Lymphoid Tissues. Lyon: LARC Press, 2001.
5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Rees J, Hann I, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Party. Blood 1998;92:2322-33.
6. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, Chen YC, et al. Correlation of cytogcnetic results with immunophenotype, genotype, clinical features and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995;84:60-8.
7. Liang DC, Chang TT, Lin XH, Lin DT, Lu MY, Chen SH, Liu HC, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 2006;20:136-41.
8. Lee MY, Chiou TJ, Bai LY, Hsiao IT, Hung GY, Chang CY, Chen PM. Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: the preliminary experience in Taiwan. J Chin Med Assoc 2004;67:117-22.
9. Teng CL, Young JH, Hsu SL, Chou G, Kuo IT, Yu CY, Hwang GY. Lactate dehydrate, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia. J Chin Med Assoc 2006;69:534-7.
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
11. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996; 88:407-18.
12. Bredeson CN, Barnett MJ, Horsman DE, Dalal BI, Ragaz J, Phillips GL. Therapy-related acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary. Leuk Lymphoma 1993;11:141-5.
13. Seiter K, Feldman EJ, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, Papageorgio C, et al. Secondary leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 2001;15:963-70.
14. Buccheri V, Matutes E, Dyer MJ, Catovsky D. Lineage commitment in biphenotypic acute leukemia. Leukemia 1993;7: 919-27.
15. Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven JG, Zomas A, et al. Outcome of biphenotypic acute leukemia. Haematologica 1999;84:699-706.
16. Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, Ramond S, et al. Adult biphenotypic acute leukemia: an entity with poor prognosis which is related to unfavorable cytogenetics and p-glycoprotein over-expression. Br J Haematol 1998;100:147-55.
17. Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, Catovsky D. Definition of acute biphenotypic leukemia. Haematologica 1997;82:64-6.